Your browser is no longer supported. Please, upgrade your browser.
NVAX [NASD]
Novavax, Inc.
Index- P/E- EPS (ttm)-9.25 Insider Own0.20% Shs Outstand74.09M Perf Week-8.15%
Market Cap14.80B Forward P/E5.50 EPS next Y35.19 Insider Trans-59.37% Shs Float73.34M Perf Month0.46%
Income-615.10M PEG- EPS next Q-3.63 Inst Own59.40% Short Float8.29% Perf Quarter-12.70%
Sales919.50M P/S16.09 EPS this Y-32.00% Inst Trans2.10% Short Ratio1.42 Perf Half Y47.09%
Book/sh14.23 P/B13.59 EPS next Y648.10% ROA-40.60% Target Price271.75 Perf Year44.37%
Cash/sh26.11 P/C7.41 EPS next 5Y0.00% ROE-125.70% 52W Range76.59 - 331.68 Perf YTD73.40%
Dividend- P/FCF25.71 EPS past 5Y9.50% ROI-38.00% 52W High-41.70% Beta1.62
Dividend %- Quick Ratio1.90 Sales past 5Y67.30% Gross Margin- 52W Low152.46% ATR14.81
Employees791 Current Ratio1.90 Sales Q/Q13143.40% Oper. Margin-65.50% RSI (14)49.09 Volatility9.18% 7.67%
OptionableYes Debt/Eq0.44 EPS Q/Q-423.70% Profit Margin-66.90% Rel Volume0.62 Prev Close203.24
ShortableYes LT Debt/Eq0.33 EarningsAug 05 AMC Payout- Avg Volume4.27M Price193.36
Recom2.00 SMA20-2.71% SMA506.67% SMA20016.33% Volume2,661,672 Change-4.86%
May-12-21Downgrade JP Morgan Overweight → Neutral $285 → $161
Dec-14-20Initiated Jefferies Buy $200
Aug-06-20Reiterated H.C. Wainwright Buy $132 → $290
Aug-05-20Upgrade JP Morgan Neutral → Overweight $275
Aug-05-20Downgrade Ladenburg Thalmann Neutral → Sell $105
Jul-16-20Reiterated H.C. Wainwright Buy $101 → $132
Jul-08-20Downgrade Ladenburg Thalmann Buy → Neutral $50 → $105
Jun-29-20Reiterated H.C. Wainwright Buy $50 → $101
Jun-29-20Reiterated B. Riley FBR Buy $74 → $106
Jun-05-20Upgrade JP Morgan Underweight → Neutral $46
May-28-20Reiterated B. Riley FBR Buy $53 → $61
May-12-20Reiterated H.C. Wainwright Buy $33 → $50
Apr-30-20Reiterated H.C. Wainwright Buy $24 → $33
Nov-27-19Resumed B. Riley FBR Buy $12
Aug-14-19Reiterated H.C. Wainwright Buy $10 → $17
Feb-28-19Downgrade Piper Jaffray Overweight → Underweight $4.50 → $0.25
Dec-18-18Initiated Ladenburg Thalmann Buy $3
Dec-11-18Initiated Oppenheimer Outperform $4
Nov-26-18Upgrade Piper Jaffray Neutral → Overweight
Sep-21-18Upgrade JP Morgan Underweight → Overweight
Jul-26-21 03:59PM  
05:55AM  
Jul-25-21 06:06AM  
05:52AM  
Jul-24-21 06:19AM  
Jul-23-21 01:53PM  
06:02AM  
Jul-22-21 02:36PM  
02:26PM  
09:20AM  
Jul-21-21 01:43PM  
Jul-20-21 05:45PM  
02:51PM  
Jul-19-21 03:12PM  
02:01PM  
12:29PM  
Jul-16-21 02:46PM  
01:37PM  
06:00AM  
Jul-15-21 05:50PM  
02:58PM  
Jul-14-21 01:49PM  
09:11AM  
06:10AM  
Jul-13-21 05:06AM  
Jul-12-21 03:09PM  
01:22PM  
Jul-11-21 06:06AM  
Jul-09-21 05:45PM  
02:22PM  
05:55AM  
Jul-08-21 01:57PM  
11:48AM  
06:51AM  
Jul-07-21 09:16PM  
04:06PM  
01:46PM  
Jul-06-21 02:21PM  
08:30AM  
Jul-02-21 05:45PM  
03:38PM  
01:39PM  
06:30AM  
06:06AM  
06:00AM  
02:36AM  
Jul-01-21 09:03PM  
02:10PM  
10:00AM  
09:04AM  
09:03AM  
09:00AM  
08:30AM  
07:29AM  
06:05AM  
Jun-30-21 05:50PM  
05:26PM  
02:39PM  
02:20PM  
01:42PM  
12:21PM  
06:09AM  
Jun-28-21 02:09PM  
09:05AM  
08:06AM  
Jun-27-21 05:51AM  
Jun-26-21 06:03AM  
06:00AM  
12:00AM  
Jun-25-21 06:00PM  
03:18PM  
Jun-24-21 05:45PM  
05:04PM  
02:00PM  
01:29PM  
Jun-23-21 05:50PM  
01:48PM  
Jun-22-21 06:38PM  
05:52AM  
Jun-21-21 02:44PM  
Jun-20-21 07:31AM  
Jun-19-21 07:00AM  
06:06AM  
Jun-18-21 02:04PM  
06:00AM  
05:47AM  
Jun-17-21 04:02PM  
03:07PM  
10:28AM  
10:19AM  
09:22AM  
08:05AM  
07:15AM  
06:00AM  
06:00AM  
Jun-16-21 07:31PM  
02:34PM  
01:48PM  
10:20AM  
09:57AM  
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. In addition, the company develops vaccine candidates for the protection against middle east respiratory syndrome, as well as that is in preclinical work associated with severe acute respiratory syndrome; and ebola virus glycoprotein vaccine candidate, as well as COVID-19 vaccine for variant strain. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Glenn Gregory MPresident, R&DJul 20Sale215.432,409518,9822,811Jul 22 05:20 PM
Glenn Gregory MPresident, R&DJul 15Option Exercise13.0810,477137,0068,465Jul 19 07:52 PM
Glenn Gregory MPresident, R&DJul 15Sale179.455,6541,014,5972,811Jul 19 07:52 PM
Erck Stanley CPresident and CEOJul 02Option Exercise80.6652,5594,239,51173,054Jul 06 05:03 PM
Erck Stanley CPresident and CEOJul 02Sale215.8952,55911,347,06620,495Jul 06 05:03 PM
Erck Stanley CPresident and CEOJul 01Option Exercise61.5952,6203,240,96573,115Jul 06 05:03 PM
Erck Stanley CPresident and CEOJul 01Sale212.8852,62011,201,51320,495Jul 06 05:03 PM
Glenn Gregory MPresident, R&DJun 17Sale183.282,411441,8872,811Jun 17 06:17 PM
Glenn Gregory MPresident, R&DJun 15Option Exercise13.1610,535138,6858,527Jun 17 06:17 PM
Glenn Gregory MPresident, R&DJun 15Sale191.425,7161,094,1302,811Jun 17 06:17 PM
EVANS GARY CDirectorJun 01Sale146.5062591,5620Jun 03 05:34 PM
Herrmann John A IIIEVP, Chief Legal OfficerMay 28Option Exercise14.832,89542,9323,170Jun 02 04:59 PM
Herrmann John A IIIEVP, Chief Legal OfficerMay 28Sale149.142,895431,748275Jun 02 04:59 PM
King Rachel K.DirectorMay 19Buy139.6470097,7482,800May 21 05:06 PM
Glenn Gregory MPresident, R&DMay 19Sale142.172,385339,0662,811May 19 05:26 PM
Glenn Gregory MPresident, R&DMay 17Option Exercise13.1610,531138,5778,523May 19 05:26 PM
Glenn Gregory MPresident, R&DMay 17Sale133.985,712765,2672,811May 19 05:26 PM
Trizzino JohnEVP, CCO, CBO & Interim CFOMay 07Sale176.6319033,559287May 07 05:10 PM
Trizzino JohnEVP, CCO, CBO & Interim CFOMay 05Option Exercise14.733,40650,1603,309May 07 05:10 PM
Trizzino JohnEVP, CCO, CBO & Interim CFOMay 05Sale185.463,022560,471287May 07 05:10 PM
Herrmann John A IIIEVP, Chief Legal OfficerApr 30Option Exercise14.822,89542,8923,170May 04 06:03 PM
Herrmann John A IIIEVP, Chief Legal OfficerApr 30Sale239.832,895694,317275May 04 06:03 PM
Trizzino JohnEVP, Chief Commercial OfficerApr 07Sale178.0319134,004287Apr 07 05:09 PM
Trizzino JohnEVP, Chief Commercial OfficerApr 05Option Exercise34.013,404115,7713,308Apr 07 05:09 PM
Trizzino JohnEVP, Chief Commercial OfficerApr 05Sale190.103,021574,292287Apr 07 05:09 PM
Herrmann John A IIIEVP, Chief Legal OfficerMar 26Option Exercise14.822,89442,8863,169Mar 30 06:10 PM
Herrmann John A IIIEVP, Chief Legal OfficerMar 26Sale186.802,894540,609275Mar 30 06:10 PM
YOUNG JAMES FDirectorMar 25Option Exercise8.9647,500425,43857,500Mar 25 06:41 PM
YOUNG JAMES FDirectorMar 23Option Exercise46.0010,000460,00020,000Mar 25 06:41 PM
YOUNG JAMES FDirectorMar 23Sale228.2210,0002,282,23110,000Mar 25 06:41 PM
MCMANUS MICHAEL A JRDirectorMar 19Sale220.784,000883,1105,951Mar 23 05:33 PM
Glenn Gregory MPresident, R&DMar 17Sale218.862,423530,3042,811Mar 17 06:35 PM
EVANS GARY CDirectorMar 15Option Exercise19.5224,500478,33040,599Mar 17 06:36 PM
Glenn Gregory MPresident, R&DMar 15Option Exercise109.9510,5311,157,8438,523Mar 17 06:35 PM
Glenn Gregory MPresident, R&DMar 15Sale198.605,7121,134,4002,811Mar 17 06:35 PM
EVANS GARY CDirectorMar 15Sale211.2124,5005,174,53616,099Mar 17 06:36 PM
Trizzino JohnEVP, Chief Commercial OfficerMar 09Sale168.0919031,937287Mar 09 07:38 PM
Trizzino JohnEVP, Chief Commercial OfficerMar 05Option Exercise14.733,40450,1483,308Mar 09 07:38 PM
Trizzino JohnEVP, Chief Commercial OfficerMar 05Sale163.463,021493,824287Mar 09 07:38 PM
Herrmann John A IIIEVP, Chief Legal OfficerFeb 26Option Exercise14.822,89542,8923,170Mar 02 05:37 PM
Herrmann John A IIIEVP, Chief Legal OfficerFeb 26Sale225.482,895652,759275Mar 02 05:37 PM
Glenn Gregory MPresident, R&DFeb 18Sale269.572,434656,1342,811Feb 18 06:59 PM
Glenn Gregory MPresident, R&DFeb 16Option Exercise13.1610,531138,5778,523Feb 18 06:55 PM
Glenn Gregory MPresident, R&DFeb 16Sale282.715,7121,614,8122,811Feb 18 06:55 PM
Trizzino JohnEVP, Chief Commercial OfficerFeb 09Sale324.5019462,953287Feb 09 07:40 PM
Trizzino JohnEVP, Chief Commercial OfficerFeb 05Option Exercise14.733,40650,1603,309Feb 09 07:40 PM
Trizzino JohnEVP, Chief Commercial OfficerFeb 05Sale290.463,022877,766287Feb 09 07:40 PM
Herrmann John A IIIEVP, Chief Legal OfficerFeb 01Option Exercise18.1515,022272,72415,297Feb 03 05:37 PM
Herrmann John A IIIEVP, Chief Legal OfficerFeb 01Sale241.5015,0223,627,789275Feb 03 05:37 PM
Trizzino JohnEVP, CMO and CBOJan 07Sale124.1750662,830287Jan 07 07:08 PM
Trizzino JohnEVP, CMO and CBOJan 05Option Exercise18.6313,756256,24317,694Jan 07 07:08 PM
Trizzino JohnEVP, CMO and CBOJan 05Sale112.0017,4071,949,522287Jan 07 07:08 PM
YOUNG JAMES FDirectorDec 31Option Exercise51.2711,000564,00011,000Jan 05 05:38 PM
DOUGLAS RICHARDDirectorDec 31Option Exercise50.001,00050,00028,500Jan 05 05:42 PM
YOUNG JAMES FDirectorDec 31Sale113.0911,0001,244,0140Jan 05 05:38 PM
Erck Stanley CPresident and CEONov 16Option Exercise37.1452,3171,942,80172,811Nov 18 06:09 PM
Erck Stanley CPresident and CEONov 16Sale90.6552,3164,742,66720,495Nov 18 06:09 PM
Erck Stanley CPresident and CEOOct 01Sale108.56221720,494Oct 01 05:39 PM
Trizzino JohnEVP, CBO and CFOSep 30Sale110.222,250248,0025,087Oct 01 05:40 PM
Erck Stanley CPresident and CEOSep 30Sale110.2312,2311,348,20020,496Oct 01 05:39 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 29Sale107.3118,0291,934,667275Sep 30 09:30 PM
Trizzino JohnEVP, CBO and CFOSep 29Sale107.2918,3211,965,6307,337Sep 30 09:28 PM
Glenn Gregory MPresident, R&DSep 29Sale107.0219,9492,134,8441,561Sep 30 09:29 PM
Erck Stanley CPresident and CEOSep 29Sale107.804,112443,26732,727Sep 30 09:27 PM
Trizzino JohnEVP, CBO and CFOSep 28Option Exercise5.9529,600176,12053,008Sep 30 09:28 PM
Erck Stanley CPresident and CEOSep 28Option Exercise5.9550,000297,50074,606Sep 30 09:27 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 28Option Exercise5.9524,750147,26243,054Sep 30 09:30 PM
Glenn Gregory MPresident, R&DSep 28Option Exercise5.9525,000148,75046,510Sep 30 09:29 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 28Sale110.3024,7502,729,87918,304Sep 30 09:30 PM
Glenn Gregory MPresident, R&DSep 28Sale110.3025,0002,757,45621,510Sep 30 09:29 PM
Trizzino JohnEVP, CBO and CFOSep 28Sale110.3025,0002,757,45625,658Sep 30 09:28 PM
Erck Stanley CPresident and CEOSep 28Sale110.3025,0002,757,45636,839Sep 30 09:27 PM
EVANS GARY CDirectorAug 18Option Exercise31.0210,500325,700332,479Aug 20 06:09 PM
Glenn Gregory MPresident, R&DAug 18Option Exercise33.5655,9211,876,52557,760Aug 20 06:14 PM
Herrmann John A IIIEVP, Chief Legal OfficerAug 18Option Exercise53.8246,2422,488,61346,517Aug 20 06:20 PM
MCMANUS MICHAEL A JRDirectorAug 18Option Exercise27.608,000220,80017,951Aug 20 06:22 PM
Trizzino JohnEVP, CBO and CFOAug 18Option Exercise50.9542,7882,179,98647,875Aug 20 06:25 PM
Trizzino JohnEVP, CBO and CFOAug 18Sale148.7842,7886,366,1825,087Aug 20 06:25 PM
MCMANUS MICHAEL A JRDirectorAug 18Sale146.008,0001,168,0009,951Aug 20 06:22 PM
Herrmann John A IIIEVP, Chief Legal OfficerAug 18Sale144.3346,2426,673,982275Aug 20 06:20 PM
Glenn Gregory MPresident, R&DAug 18Sale145.2055,9218,119,8601,839Aug 20 06:14 PM
EVANS GARY CDirectorAug 18Sale150.4410,5001,579,620321,979Aug 20 06:09 PM